The recent decline and disappearance of many amphibians around the world is thought to be the sign of an impending sixth mass extinction that is driven by disease, habitat loss and pollution. Reproductive technologies are now required to establish captive colonies followed by reintroduction into suitable habitats. The AMPHIPLEX method is a hormone mixture that has successfully stimulated spawning in several amphibians. However, its extensive application requires further experimentation and knowledge regarding the basic neuroendocrine control of reproduction in amphibians. The role of the catecholamine neurotransmitter dopamine in the regulation of spawning and gonadotropin synthesis was investigated using multiple time- and dose-related approaches in the field and laboratory. These end points were explored in two distantly-related frog species: the Northern leopard frog (Lithobates pipiens) and the Western clawed frog (Silurana tropicalis). Northern leopard frogs were injected during the natural breeding season with three doses of a gonadotropin-releasing hormone agonist (GnRH-A) (0.1 μg/g , 0.2 μg/g and 0.4 μg/g) alone and in combination with two doses of the selective dopamine receptor D2 antagonist metoclopramide (MET) (5 μg/g and 10 μg/g). Injected animals were allowed to breed in mesocosms in an outdoor field. Time to amplexus and oviposition were assessed, and egg mass release, incidences of amplexus, egg mass weight, total egg numbers and fertilization rates were measured. The results revealed no statistically significant interaction between GnRH-A and MET on amplexus and oviposition. A series of GnRH-A dose-response spawning studies were conducted in the Western clawed frog. The current findings indicate that partial ovulation, male sexual behavior and fertilization can be induced by 4 μg/g of GnRH-A alone and in combination with 10 μg/g of MET. This represents a first step towards understanding basic neuroendocrine reproductive mechanisms in this species. These spawning results were paired with a second end point which explored the molecular mechanisms of gonadotropin synthesis in response to GnRH-A and MET alone and in combination. Pituitary gene expression results in the Northern leopard frog indicate a potentiating action of MET when combined with GnRH-A on the mRNA levels of gonadotropin subunits 36 hours following injection. The postulated mechanisms of action are through the upregulation of gonadotropin-releasing hormone receptor 1 and the downregulation of dopamine receptor D2. Such gene expression pathways were similarly explored in the Western clawed frog, however no significant changes in pituitary gonadotropin and receptor gene expression were present at 12 hours post-injection. The hypothesized inhibitory action of dopamine was supported by pituitary gene expression analysis, but not by spawning outcome. The results from this study provide a fundamental framework for future time- and dose-response investigations to improve current spawning methods in amphibians.

京都大学 / 新制・論文博士 / 博士(医学) / 乙第13439号 / 論医博第2238号 / 新制||医||1054(附属図書館) / (主査)教授 万代 昌紀, 教授 小杉 眞司, 教授 稲垣 暢也 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

In this study, the structure and function of gonadotropin-releasing hormone (GnRH) in different vertebrate species, in the classes Aves, Reptilia and Pisces was investigated. Acetic acid extracts were subjected to gel filtration chromatography and semipreparative high performance liquid chromatography (HPLC) to partially purify the GnRHs. The GnRH immunoreactivity was then characterized by analytical HPLC, and by assaying HPLC fractions by radioimmunoassay with region-specific antisera generated against mammalian GnRH, Gln⁸-GnRH and Trp⁷,Leu⁸-GnRH and assessing luteinizing hormone (LH)-releasing activity of fractions in a chicken dispersed anterior pituitary cell bioassay. Five GnRH molecular forms have thusfar been structurally characterized in vertebrate brain. In mammals a GnRH with the structure pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ has been demonstrated in the hypothalamus (Matsuo et al., 1971; Burgus et al., 1972). Gln⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH were present in chicken hypothalamus (King and Millar, 1982a, 1982c; Miyamoto et al., 1983, 1984), Trp⁷,Leu⁸-GnRH in salmon brain (Sherwood et al., 1983) and Tyr³,Leu⁵,Glu⁶,Trp⁷,Lys⁸-GnRH in lamprey brain (Sherwood et al., 1986). In ostrich (Struthio camelus) hypothalamus two GnRHs with identical properties to Gln⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH have been demonstrated, as well as four other LR-releasing factors with different chromatographic and immunological properties to any of the known naturally-occurring GnRHs. Since Gln⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH were also present in chicken hypothalamus it appears likely that these two GnRHs occur in all birds. In alligator (Alligator mississippiensis) brain only two GnRHs were detected. These forms co-eluted with Gln⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH in two HPLC systems. They cross-reacted similarly to the two synthetic peptides with antisera directed against mammalian GnRH and Gln⁸-GnRH and released LH from chicken dispersed anterior pituitary cells in a similar manner to the synthetic peptides. The Archosaurs (alligators and crocodiles) are believed to be closely related to birds and therefore it seems likely that they should have identical GnRHs. In skink (Calcides ocellatus tiligugu) brain one GnRH, which co-eluted with His⁵,Trp⁷,Tyr⁸-GnRH, was demonstrated. Two other lizards (Cordylis nigra and Pordarcis s. sicula) have been studied (Powell et al., 1985; R.C. Powell, G. Ciarcia, V. Lance, R.P. Millar and J.A. King, submitted). In c. nigra four immunoreactive GnRHs were detected, two of which co-eluted released chicken LH similarly to, Trp⁷,Leu⁸-GnRH and with, and His⁵,Trp⁷,Tyr⁸-GnRH. In P. s. sicula a GnRH molecular form similar to Trp⁷,Leu⁸-GnRH occurred as well as two novel GnRHs. It thus appears that Gln⁸-GnRH does not occur in lower reptiles, but His⁵,Trp⁷,Tyr⁸-GnRH and/or Trp⁷,Leu⁸-GnRH do. His⁵,Trp⁷,Tyr⁸-GnRH appears to he a widespread GnRH, occurring in vertebrates as diverse as birds and elasmobranch fish. In dogfish (Poroderma africanum) brain seven factors, which stimulated release of LH from chicken dispersed anterior pituitary cells, were separated on analytical HPLC. Two of these factors were partially characterized as Trp⁷,Leu⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH. Three of the other forms cross-reacted with GnRH antisera, but appear to be novel GnRHs. In teleost (Coris julis) brain two GnRHs similar to Trp⁷,Leu⁸-GnRH and His⁵,Trp⁷,Tyr⁸-GnRH were present. These two GnRHs therefore appear to occur in both fish species studied. Trp⁷,Leu⁸-GnRH is widespread amongst teleost fish (Jackson and Pan, 1983; Sherwood et al., 1983; Breton et al., 1984; Sherwood et al., 1984; King and Millar, 1985). From these data it seems evident that the mammalian GnRH molecular form occurs only in mammals and amphibians, Gln⁸-GnRH in birds and higher reptiles, and Trp⁷,Leu⁸-GnRH in gnathostomes. His⁵,Trp⁷, Tyr⁸-GnRH appears to he present in numerous different vertebrates. Tyr³,Leu⁵,Glu⁶,Trp⁷,Lys⁸-GnRH has thus far only been detected in lamprey brain. A number of novel GnRHs, whose structures have not been elucidated are present.

Post-traumatic stress disorder is a disorder characterized by an inability to extinguish traumatic memories and heightened reactivity to emotional stimuli. Due to the heightened resistance of traumatic memories to extinction, treatment for PTSD has been challenging and is limited to behavioral therapies targeted at reducing responsivity to threatening stimuli. Currently there are no standard pharmacological interventions that are specific to PTSD; rather, drugs used appear to target symptoms of some of the co-morbid conditions, such as anxiety (e.g. benzodiazepines) or depression (antidepressants) - which may also affect fear-memory. In this thesis, we explore the effects of natural health products (NHPs) including naturally occurring peptides and some medical botanicals on fear memory in order to explore the efficacy of natural products as potential pharmacological targets for fear-based disorders. Fear-conditioning has been used effectively in both rodents and humans to study fear-learning. Fear-conditioning is a learning paradigm during which an unconditioned aversive stimulus (such as foot shock) is paired with a neutral stimulus (such as light or tone), such that the neutral stimulus becomes associated with aversion. Fear-learning has several well-characterized stages, including acquisition, consolidation, reconsolidation, expression, and extinction that can be manipulated in order to study the pharmacological action(s) on the attenuation of learned-fear. Blockade of reconsolidation, the state during which formed memories are briefly rendered susceptible to change following recall, may provide a window of opportunity to pharmacologically diminish learned fear. In Chapter 1 of the thesis, we discuss fear-conditioning as a pre-clinical model of PTSD to explore the effects of novel pharmacological treatments on the reconsolidation process in rodents. We ultimately hope to provide a framework for translational work in humans for attenuating conditioned responses to trauma-related stimuli among humans with PTSD. In Chapter 2, we present evidence that systemic administration of gastrin-releasing peptide attenuates the reconsolidation of conditioned fear in rodents. Similarly, in chapter 3, we explore the effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on the reconsolidation of learned-fear, and provide evidence that cannabinoid molecules may similarly prove effective at blocking the reconsolidation of conditioned fear memories. In chapter 4, we present evidence demonstrating that extracts of medical botanical Souroubea sympetala and its components may similarly block reconsolidation of conditioned fear-memory, and also exert more general anxiolytic-like activity in the elevated plus maze paradigm. Finally, in chapter 5 a general discussion considers the relative therapeutic potential for future human clinical trials of each of the three tested groups of compounds.

No description available.

Two studies were conducted to evaluate the effects of 5 or 7 d post-AI GnRH on first service PR, plasma P4, and CL volume in lactating dairy cows synchronized using 72 h Cosynch. All cows were synchronized and randomly assigned to one of three treatment groups: Control – no additional GnRH; 5 d – GnRH 5 d after TAI; 7 d – GnRH 7 d after TAI. In the first study, P4 concentrations were evaluated in samples collected at five separate times and CL volume and number were recorded at 30 d pregnancy examination for Holstein (n = 77) and Jersey (n = 33) cows. GnRH treatment did not affect PR (Control - 47.2%, 5 d GnRH - 40.5%, 7 d GnRH – 44.7%) or P4, but increased TCLV compared to controls (Control – 7.33 cm3, 5 and 7 d GnRH – 10.77 cm3). Incidence of accessory CL increased PR (94.7 vs. 60.6%), P4 (6.95 vs. 5.88 ng/mL), and TCLV (15.51 vs. 6.78 cm3) compared to cows with a spontaneous CL. Cows classified as cycling based on P4 evaluation had significantly higher PR than acyclic cows (54.4 vs. 16.1%). In the second study, Holstein cows (n = 1055) were submitted to the same experimental protocol and evaluated for first service PR. Post-AI GnRH treatment did not significantly affect PR. Primiparous cows (32.8%) tended to have higher PR than multiparous cows (27.6%), but GnRH treatment had no influence on this relationship. In conclusion, GnRH post-AI did not affect PR. Further evaluation of accessory CL incidence is warranted as it significantly affected PR. (Abbreviations: AI – artificial insemination, CL – corpus luteum, PR – conception rate, P4 – progesterone, TCLV – total corpus luteum volume) / Master of Science

Huang, Hui. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 141-154). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

In a HEK 293 cell line stably expressing seabream GHS-R1a (sbGHS-R1a), we found that a synthetic growth hormone secretagogue (GHS) increased [ 3H]-inositol phosphate production, clearly indicating coupling of this receptor to Gq/11-proteins. Using Western blotting, we found that GHS could also stimulate extracellular signal-regulated kinases 1 and 2 (ERK1/2), and that this response was inhibited by the MEK inhibitor U0126. For both the [3H]-inositol phosphate and ERK1/2 assays, the presence of the GHS-R antagonist D-Lys(3)-GHRP-6 significantly inhibited the GHS-stimulated activities, and in addition inhibited basal activities by 50% and 40%, respectively. These results showed that sbGHS-R1a is a constitutively active receptor and the antagonist D-Lys(3)-GHRP-6 is an inverse agonist. We also proposed that the expression of sbGHS-Rs was involved in the regulation of cell apoptosis. / Oligomerization of the human GHS-Rs (hGHS-Rs) was explored by transient transfection of the hGHS-Rs in HEK 293 cells followed by co-immunoprecipitation of differentially epitope-tagged forms of the receptors and bioluminescence resonance energy transfer 2 (BRET2) studies. (Abstract shortened by UMI.) / The concept that G protein-coupled receptors (GPCRs) exist and potentially function as dimers and/or higher oligomers has progressed from hypothesis to being widely accepted recently. Oligomerization of GPCRs has been increasingly noted in the regulation of the biological activity of the receptors. The growth hormone secretagogue receptor 1a (GHS-R1a) is a GPCR which principally regulates the pulsatile release of growth hormone from the pituitary gland. The GHS-R exists in two forms: GHS-R1a being a constitutively-active GPCR with 7 transmembrane (TM) domains, and GHS-R1b being a truncated version of type 1a but having only 5 TM domains. The endogenous agonist for GHS-R1a is ghrelin which exerts a wide range of physiological actions, but the function of GHS-R1b is still unclear. Since the tissue distribution patterns of the two isoforms of GHS-R are different, the objective of the present study is to explore the mechanisms of cell signalling of GHS-R1a and to determine the extent and importance of interactions between these two receptor isoforms. / Leung Po Ki. / "July 2005." / Adviser: Helen Wise. / Source: Dissertation Abstracts International, Volume: 67-07, Section: B, page: 3728. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (p. 189-210). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / School code: 1307.

Meduloblastoma é o tumor intracranial mais comum em crianças, provavelmente derivado de células precursoras da camada granular externa do cerebelo durante seu desenvolvimento. O tratamento padrão consiste em cirurgia, radioterapia e quimioterapia, que produzem graves sequelas nos pacientes e garantem uma sobrevida baixa, o que demonstra a necessidade de novas alternativas terapêuticas para a doença. Evidências demonstram que o receptor do peptídeo liberador de gastrina (GRPR) está superexpresso em diversos tumores humanos, assim como seu agonista (GRP) pode atuar como um fator de crescimento autócrino em tumores cerebrais. No presente estudo, avaliamos a expressão de GRPR e o efeito de seus agonistas, bombesina (BB) e GRP, além do antagonista RC-3095, sobre a viabilidade celular de linhagens de meduloblastoma humano DAOY, D283 e ONS76. Mostramos que meduloblastomas, apesar de expressarem GRPR, não têm sua viabilidade celular afetada por agonistas e antagonista desse receptor. Uma vez que há evidências de que BDNF (fator neurotrófico derivado de cérebro) esteja relacionado à diferenciação celular em meduloblastomas, também avaliamos o efeito de BDNF sobre a viabilidade celular das linhagens de meduloblastoma humano. As linhagens DAOY e D283 tiveram sua viabilidade celular reduzida pela presença de BDNF. Uma vez que a via da PKA tem sido implicada na iniciação e progressão de vários tumores, também avaliamos o efeito de rolipram, um inibidor de fosfodiesterase tipo IV, sobre a viabilidade celular das linhagens de meduloblastoma humano, sendo que rolipram reduziu a viabilidade celular de todas as linhagens estudadas. Os receptores de BDNF e a via da PKA podem, portanto, ser alvos moleculares promissores para o desenvolvimento de novas terapias para meduloblastomas. / Medulloblastoma is the most common intracranial tumor in children and is believed to arise from the precursor cells of the external granule layer of the developing cerebellum. The standard treatment, consisting of surgery, craniospinal radiotherapy and chemotherapy, produces severe sequelae in patients and provides a poor overall survival, indicating the need for new therapeutic alternatives for treating this disease. Evidences show that the gastrin releasing peptide receptor (GRPR) is overexpressed in various human tumors and its agonist (GRP) can act as an autocrine growth factor in brain tumors. In the present study, we evaluated GRPR expression, as well as the effect of its agonists, bombesin (BB) and GRP, and its antagonist RC-3095, over cell viability of the human medulloblastoma cell lines DAOY, D283 and ONS76. We found that medulloblastomas, in spite of expressing GRPR, do not have its viability affected by the presence of agonists and antagonist of this receptor. Since there are evidences that BDNF (brain-derived neurotrophic factor) is related to cell differentiation in medulloblastomas, we also evaluated the effect of BDNF over the viability of medulloblastoma cell lines. The viability of the cell lines DAOY and D283 was reduced by the presence of BDNF. Since the PKA pathway has been implicated in the initiation and progression of various tumors, we also evaluated the effect of rolipram, a phosphodiesterase IV inhibitor, over the viability of the same medulloblastoma cell lines and we found that rolipram inhibited the viability of all the cell lines studied. BDNF receptors, as well as the PKA pathway, may be therefore promising molecular targets for the development of new therapies for treating medulloblastomas.

Aktivierte G-Protein-gekoppelte Rezeptoren (GPCR) werden schnell desensitisiert, internalisiert und anschließend entweder lysosomal degradiert oder zur Plasmamembran (PM) recycelt. Zur Resensitisierung der Zellen tragen neben recycelten auch neusynthetisierte Rezeptoren bei. Die Überlagerung beider Prozesse erschwert die Untersuchung des Rezeptorrecyclings. In dieser Arbeit sollte mit Hilfe des photokonvertierbaren Fluoreszenzproteins Kaede eine Technik entwickelt werden, mit der es möglich ist Recycling- von Neusyntheseprozessen zu trennen und das Recycling von GPCR mikroskopisch in Echtzeit zu beobachten. Als Modellproteine wurden der Vasopressin-1a-Rezeptor V1aR (recycelnder Rezeptor), der Vasopressin-2-Rezeptor V2R (degradierter Rezeptor) und der Corticotropin-Releasing Factor-Rezeptor Typ 1 (CRF1R) verwendet, wobei bei Letzterem untersucht werden sollte, ob er nach Stimulation zur PM zurücktransportiert wird. Da Kaede als fluoreszierendes Protein mit den GPCR fusioniert wird, wurde zunächst überprüft, ob es die Eigenschaften der Rezeptoren verändert und generell für Transportstudien geeignet ist. Eventuell könnte die bereits publizierte Tetramerisierung von Kaede seine Anwendung verhindern oder erschweren. Mittels Fluoreszenz-Korrelationsspektroskopie konnte gezeigt werden, dass Kaede nicht tetramerisiert, wenn es an ein Membranprotein fusioniert ist. Außerdem konnte in in vitro- und Zellkulturexperimenten belegt werden, dass die native und die photokonvertierte Form von Kaede gleichermaßen stabil sind. Darüber hinaus zeigten Kaede-fusionierte GPCR sowohl in Kolokalisationsstudien als auch in Agonistbindungs- und Rezeptoraktivierungsexperimenten die gleichen Eigenschaften wie CFP- bzw. die unfusionierte Rezeptoren. Lediglich die Expression der Kaede-fusionierten Rezeptoren war geringer. Parallel wurde anhand der bereits publizierten Kaede-Struktur versucht, die Tetramerisierung des Proteins durch den Austausch interagierender Aminosäuren zu unterbinden. Die eingeführten Mutationen bewirkten aber eine Fehlfaltung des Proteins und damit den Verlust der Fluoreszenz. Da zuvor gezeigt werden konnte, dass Kaede-fusionierte Membranproteine nicht tetramerisieren und nicht die Eigenschaften der fusionierten Proteine verändern, war monomerisiertes Kaede zur Untersuchung des Rezeptorrecyclings nicht notwendig. Im zweiten Teil der Arbeit wurde mit Hilfe von Kaede-Fusionsproteinen und mikroskopischer Testsysteme das noch unbekannte Recyclingverhalten des CRF1R untersucht. Hierfür wurden die Kaede-fusionierten Rezeptoren in eukaryotischen Zellen exprimiert und mit Agonisten internalisiert. Die internalisierten Rezeptoren wurden in Endosomen selektiv mit UV-Strahlung photokonvertiert. Anschließend wurde der Transport der photokonvertierten Form verfolgt. Sowohl beim CRF1R als auch beim V1aR wurden Signale in der PM detektiert, beim V2R hingegen nicht. Dies zeigt, dass es sich beim CRF1R um einen recycelnden Rezeptor handelt. Die als Kontrolle eingesetzten Rezeptoren verhielten sich in diesem Experiment wie erwartet: Der V1aR wurde zur PM zurücktransportiert, der V2R nicht. Diese Ergebnisse konnten mit Hilfe biochemischer und durchflusscytometrischer Experimente bestätigt werden. Die Internalisierung des CRF1R verläuft Clathrin-vermittelt in Anwesenheit von β-Arrestin. Je nach Stabilität der β Arrestin-Interaktion unterscheidet man zwei Klassen von Rezeptoren: Klasse A-Rezeptoren interagieren transient mit β Arrestin und können recyceln. Im Gegensatz dazu gehen Klasse B-Rezeptoren eine stabile Interaktion mit β Arrestin ein und werden nach Internalisierung degradiert. In mikroskopischen Untersuchungen konnte für die aktivierten CRF1R und V1aR eine Rekrutierung von β Arrestin zur PM und eine transiente Interaktion mit β Arrestin gezeigt werden (Klasse A-Rezeptoren). Für den V2R wurde dagegen eine stabile Interaktion mit β Arrestin beobachtet (Klasse B-Rezeptor). Diese Daten stützen die Ergebnisse des Kaede-basierten Recyclingversuchs und zeigen, dass der CRF1R ein recycelnder Rezeptor ist. Ferner wurde untersucht, ob der CRF1R zu den schnell oder langsam recycelnden Rezeptoren zählt. Schnell recycelnde Rezeptoren werden direkt aus frühen Endosomen, langsam recycelnde hingegen über das Trans-Golgi-Netzwerk (TGN) bzw. über Recycling-Endosomen zur PM transportiert. Als Marker für das TGN oder die Recycling-Endosomen wurde Rab11 verwendet. In Kolokalisationsstudien konnte gezeigt werden, dass der CRF1R den langsam recycelnden Rezeptoren zugeordnet werden kann. Zusammenfassend konnte in dieser Arbeit belegt werden, dass Kaede als Fusionspartner für Membranproteine genutzt werden kann um deren Transport in Echtzeit zu studieren. Damit wurde erstmals eine mikroskopische Methode etabliert, die es erlaubt recycelnde von neusynthetisierten Rezeptoren zu unterscheiden. Mit Hilfe dieser Methode war es möglich zu zeigen, dass der CRF1R ein recycelnder Rezeptor ist. / Upon ligand binding and receptor activation, G protein-coupled receptors (GPCR) are rapidly desensitized, internalized and subsequently degraded in lysosomes or recycled back to the plasma membrane. Resensitization of the cell is enabled by both recycling receptors and newly synthesized receptors. The overlap of recycling and synthesis processes largely complicates the study of GPCR recycling mechanisms. One aim of this thesis was to develop a new microscopic technique for real-time visualization of GPCR recycling using the photoconvertible Kaede protein allowing to differentiate newly synthesized from recycling receptors. As model proteins, the V1aR (recycling receptor), the V2R (degraded receptor) and the CRF1R were used. In the case of the CRF1R, it was unknown whether this receptor recycles to the plasma membrane following agonist-promoted internalization. The study of the CRF1R recycling behaviour was another objective of this work. As the Kaede protein is fused C-terminally to the GPCRs, an influence on the pharmacological and trafficking properties of the receptors must be excluded. The previously published tetramerization of Kaede, for example, might hinder or even prevent its usability. To assess for the applicability of Kaede, fluorescence correlation spectroscopy experiments were performed and it was demonstrated that Kaede fused to membrane proteins cannot form tetramers in contrast to the soluble form. In vitro studies and experiments in cell culture revealed that both the native and the photoconverted Kaede are equally stable. Moreover Kaede-fused GPCR displayed the same pharmacological and trafficking properties as the untagged or CFP-tagged receptors. Only the expression levels of the Kaede fusion proteins were reduced, yet this did not affect the microscopic experiments. In parallel to these experiments, the interacting amino acids of the tetrameric Kaede were substituted according to the previously published crystal structure of the protein. Unfortunately, these mutations induced protein misfolding thereby causing loss of fluorescence functions. However, since it could be shown that membrane protein-fused Kaede cannot tetramerize, the monomerized Kaede was no more essential for the microscopic study of receptor recycling. In the second part of this work, Kaede-fusions were used to study the recycling behaviour of the CRF1R and the V1aR and V2R control proteins by the novel real-time recycling assay at the laser scanning microscope. To this end, HEK 293 cells expressing the Kaede-fused receptors were treated with agonist to induce receptor internalization. Internalized receptors were selectively photoconverted in endosomes using UV-irradiation and the subcellular fate of the new fluorescence signals was studied. In the case of the CRF1R, signals of the photoconverted receptors could be detected in the plasma membrane indicating that the CRF1R belongs to the family of recycling receptors. The control receptors showed the expected results: The V1aR recycled back to the plasma membrane whereas the V2R did not. These results were confirmed with biochemical and flow cytometry measurements. The CRF1R internalizes in a clathrin-dependent way via the adaptor protein AP2, dynamin and β arrestin. Depending on the stability of the resulting receptor-β-arrestin-complex, two classes of receptors can be differentiated. Class A receptors are recycling receptors undergoing a more transient β-arrestin interaction. In contrast, class B receptors stably interact with β-arrestin and are degraded after internalization. In the case of the CRF1R and V1aR, microscopic analyzes demonstrated that β arrestin transiently interacts with the stimulated CRF1R and V1aR indicating again that these receptors are recycling GPCRs (class A receptors). The V2R, in contrast, revealed a stable interaction (class B receptor). Moreover, it was studied whether the CRF1R recycles rapidly or more slowly to the plasma membrane. Rapidly recycling receptors are recruited out of early endosomes whereas slowly recycling receptors pass the trans-golgi-network or recycling endosomes before reaching the cell surface. Rab11 colocalization studies demonstrated that the CRF1R belongs to the family of slowly recycling receptors. In conclusion, a novel microscopic technique was established allowing to study GPCR recycling in real-time and to differentiate recycling and synthesis processes. Moreover, it was shown that the CRF1R belongs to the family of recycling receptors. The Kaede technique seems to be very well suited to study membrane protein trafficking in general.